Skip to main content
. 2022 Sep 8;11(18):2772. doi: 10.3390/foods11182772

Table 4.

Studies using quercetin in the treatment of models of complicated pregnancies, including preeclampsia. The up arrow ↑ represents increase, down arrow ↓ represents decrease.

Reference Type of Study Dose Duration Maternal Outcomes Embryonic, Fetal and Neonatal Outcomes
Li et al., 2020 [12] Experimental (rats subjected to preeclampsia model) The authors did not inform the dose of treatment. The authors did not inform the duration of treatment. ↓ Systolic blood pressure;
↓ Proteinuria.		 Reversed imbalance of angiogenic factors production in the placenta;
↓ Placental growth factor;
↓ Placental expression of TNF-α, IL-6, and MCP-1 levels;
↓ Placental MDA;
↑ Placenta weight;
↓ Reabsorbed fetuses %;
↑ Pups weight;
↑ Placenta weight.
Sun et al., 2020 [68] Experimental (rats subjected to gestational hypertension) 10 mg/kg, 20 mg/kg, or 50 mg/kg. From gestational day 14 to gestational day 21. ↓ Systolic and diastolic blood pressure;
↓ Plasma level of ET-1, sFLT1;
↑ Plasma level of VEGF;
↓ Plasma levels of TNF-α and IL-6, and ↑ IL-10.		 ↓ ET-1, ETAR expression in placenta tissue;
↑ Fetal weight;
Did not change placental weight;
↑ Fetal weight/
Placenta weight;
↓ Reabsorbed fetuses %.
Tanir et al., 2005 [23] Experimental (rats subjected to preeclampsia model) 10 mg/kg Single administration at gestational day 17. Did not change blood pressure;↓ Plasma MDA levels;
↓ Erythrocyte CAT and SOD levels;
↓ Proteinuria.		 Did not change the birth weight of pups;
↑ Neonatal survival (higher percentages of liveborn pups and lower rates of dead pups).
Yang et al., 2019 [67] Experimental (rats subjected to preeclampsia model) 2 mg/kg From gestational day 4 to gestational day 19. ↓ Proteinuria;
↓ Plasma MDA levels;
Did not change TNF-α;
↓ Plasma levels of IL-6.		 Did not change placental MDA;
Did not change placental expression of TNF-α and IL-6;
Did not change relative mRNA expression of uterus VEGF and sFlt-1.